The management of esophagogastric junction (EGJ) cancer is multidisciplinary, and due to its specificity, requires a high-volume center with high medical and surgical expertise. The aim of this narrative review was to critically analyze the evidence and guidelines in the literature and examine the tips and tricks in surgical and medical treatment to increase the long-term outcome of patients with this kind of tumor.Esophagogastric junction (EGJ) carcinoma represents a specific site of disease, given the opportunities for multimodal clinical care and management and the possibilities of combined treatments. It encompasses various clinical subgroups of disease that are heterogeneous and deserve different treatments; therefore, the guidelines have progressively evolved over time, considering the evidence provided by clinical trials. The aim of this narrative review was to summarize the main evidence, which orientates the current guidelines, and to collect the main ongoing studies to address existing gray areas.
Tondolo, V., Casà, C., Rizzo, G., Leone, M., Quero, G., Alfieri, V., Boldrini, L., Bulajic, M., Corsi, D. C., Micciché, F., Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review, <<CANCERS>>, 2023; 15 (9): 1-16. [doi:10.3390/cancers15092597] [https://hdl.handle.net/10807/280164]
Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review
Tondolo, Vincenzo;Rizzo, Gianluca;Quero, Giuseppe;Boldrini, Luca;Corsi, Domenico Cristiano;
2023
Abstract
The management of esophagogastric junction (EGJ) cancer is multidisciplinary, and due to its specificity, requires a high-volume center with high medical and surgical expertise. The aim of this narrative review was to critically analyze the evidence and guidelines in the literature and examine the tips and tricks in surgical and medical treatment to increase the long-term outcome of patients with this kind of tumor.Esophagogastric junction (EGJ) carcinoma represents a specific site of disease, given the opportunities for multimodal clinical care and management and the possibilities of combined treatments. It encompasses various clinical subgroups of disease that are heterogeneous and deserve different treatments; therefore, the guidelines have progressively evolved over time, considering the evidence provided by clinical trials. The aim of this narrative review was to summarize the main evidence, which orientates the current guidelines, and to collect the main ongoing studies to address existing gray areas.File | Dimensione | Formato | |
---|---|---|---|
cancers-15-02597-v2.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
325.39 kB
Formato
Adobe PDF
|
325.39 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.